vTv Therapeutics (VTVT) Stock: Buy, Sell, or Hold?
VTVT - vTv Therapeutics Inc. Class A Common Stock
$25.55
-1.61 (-5.93%)
▼
5d:
-3.73%
30d:
-16.86%
90d:
-17.63%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When VTVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: VTVT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: VTVT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: VTVT is currently trading at $25.55, which is considered oversold relative to its 30-day fair value range of $27.92 to $31.39.
Technical Outlook: Technically, VTVT is in a downtrend. The price is currently testing key support at $25.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: VTVT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $56.17 (+119.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VTVT is in a downtrend. The price is currently testing key support at $25.35. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.9% recently.
Market Sentiment: VTVT scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $56.17 (+119.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$27.92 -
$31.39
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.9%)
- BULLISH: Trading 119.8% below Wall St target ($56.17)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$27.92 -
$31.39
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$25.35
Resistance Level
$31.22
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.83
Wall Street Target
$56.17
(+119.8%)
Profit Margin
-12.9%
Share & Embed Analysis
Last updated: October 24, 2026 2:28 AM ET
Data refreshes hourly during market hours. Next update: 3:28 AM
Data refreshes hourly during market hours. Next update: 3:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VTVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 53 HOLD |
